ID

13162

Descripción

A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I); ODM derived from: https://clinicaltrials.gov/show/NCT00317642

Link

https://clinicaltrials.gov/show/NCT00317642

Palabras clave

Versiones (1)
  1. 20/1/16 20/1/16 -
Titular de derechos de autor

CC BY-NC 3.0

Subido en

20 de enero de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Acute Myelogenous Leukemia NCT00317642

Inglés

Eligibility Acute Myelogenous Leukemia NCT00317642

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
have a diagnosis of acute myelogenous leukemia (aml) according to world health organization (who) classification
Descripción

AML

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023467
relapsed after receiving up to 2 prior induction regimens (i.e. first or second relapse)or are refractory to not more than one prior combination chemotherapy induction regimen
Descripción

relapsed or refractory

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
be ≥ 55 years of age
Descripción

age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
have an eastern cooperative oncology group (ecog) score of 0-2
Descripción

ecog score

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
be able to comply with study procedures and follow-up examinations
Descripción

compliance

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1321605
be nonfertile or agree to use birth control during the study through the end of treatment visit and for at least 90 days after the last dose of study drug
Descripción

fertility and contraception

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0015895
UMLS CUI [2]
C0700589
have adequate liver and renal function as indicated by certain laboratory values
Descripción

liver and renal function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0232741
UMLS CUI [2]
C0232804
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
received previous treatment with clofarabine
Descripción

clofarabine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0092777
received bolus, intermediate or high-dose cytarabine as induction therapy unless certain remission criteria are met
Descripción

cytarabine

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0010711
have received a hematopoietic stem cell transplant (hsct) within the previous 3 months
Descripción

hematopoietic stem cell transplant

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0472699
have moderate or severe graft versus host disease (gvhd), whether acute or chronic
Descripción

graft versus host disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018133
are receiving any other chemotherapy or investigational therapy. patients must have been off prior aml therapy for at least 2-6 weeks prior to entering study.
Descripción

chemotherapy or investigational therapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0392920
UMLS CUI [2]
C0013230
have a psychiatric disorder that would interfere with consent, study participation, or follow-up
Descripción

psychiatric disorder that would interfere with consent, study participation, or follow-up

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
have an active, uncontrolled infection
Descripción

infection

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009450
have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system
Descripción

severe concurrent disease, or have a history of serious organ dysfunction

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009488
have been diagnosed with another malignancy, unless disease-free for at least 5 years; patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed; patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed.
Descripción

malignancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0006826
have clinical evidence suggestive of central nervous system (cns) involvement with leukemia unless lumbar puncture confirms absence of leukemic blasts in the cerebrospinal fluid(csf)
Descripción

cns leukemia

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1332884
known hiv positivity
Descripción

HIV

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019682
are pregnant or lactating
Descripción

pregnancy or lactation

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
Volver a la parte superior de la página

Similar models

Eligibility Acute Myelogenous Leukemia NCT00317642

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
AML
Item
have a diagnosis of acute myelogenous leukemia (aml) according to world health organization (who) classification
boolean
C0023467 (UMLS CUI [1])
relapsed or refractory
Item
relapsed after receiving up to 2 prior induction regimens (i.e. first or second relapse)or are refractory to not more than one prior combination chemotherapy induction regimen
boolean
C0392920 (UMLS CUI [1])
age
Item
be ≥ 55 years of age
boolean
C0001779 (UMLS CUI [1])
ecog score
Item
have an eastern cooperative oncology group (ecog) score of 0-2
boolean
C1520224 (UMLS CUI [1])
compliance
Item
be able to comply with study procedures and follow-up examinations
boolean
C1321605 (UMLS CUI [1])
fertility and contraception
Item
be nonfertile or agree to use birth control during the study through the end of treatment visit and for at least 90 days after the last dose of study drug
boolean
C0015895 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
liver and renal function
Item
have adequate liver and renal function as indicated by certain laboratory values
boolean
C0232741 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
clofarabine
Item
received previous treatment with clofarabine
boolean
C0092777 (UMLS CUI [1])
cytarabine
Item
received bolus, intermediate or high-dose cytarabine as induction therapy unless certain remission criteria are met
boolean
C0010711 (UMLS CUI [1])
hematopoietic stem cell transplant
Item
have received a hematopoietic stem cell transplant (hsct) within the previous 3 months
boolean
C0472699 (UMLS CUI [1])
graft versus host disease
Item
have moderate or severe graft versus host disease (gvhd), whether acute or chronic
boolean
C0018133 (UMLS CUI [1])
chemotherapy or investigational therapy
Item
are receiving any other chemotherapy or investigational therapy. patients must have been off prior aml therapy for at least 2-6 weeks prior to entering study.
boolean
C0392920 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
psychiatric disorder that would interfere with consent, study participation, or follow-up
Item
have a psychiatric disorder that would interfere with consent, study participation, or follow-up
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
infection
Item
have an active, uncontrolled infection
boolean
C0009450 (UMLS CUI [1])
severe concurrent disease, or have a history of serious organ dysfunction
Item
have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system
boolean
C0009488 (UMLS CUI [1])
malignancy
Item
have been diagnosed with another malignancy, unless disease-free for at least 5 years; patients with treated nonmelanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed; patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed.
boolean
C0006826 (UMLS CUI [1])
cns leukemia
Item
have clinical evidence suggestive of central nervous system (cns) involvement with leukemia unless lumbar puncture confirms absence of leukemic blasts in the cerebrospinal fluid(csf)
boolean
C1332884 (UMLS CUI [1])
HIV
Item
known hiv positivity
boolean
C0019682 (UMLS CUI [1])
pregnancy or lactation
Item
are pregnant or lactating
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial